Member Info for Soupdragon78

Lol!

Certainly won't be happy if the company think they can leave it till the end of March to communicate.

https://m.economictimes.com/industry/healthcare/biotech/pharmaceuticals/aurobindo-inks-pact-to-acquire-australian-pharma-firms-product/articleshow/66604107.cms

Meanwhile Colchicine trials results are interesting reading. Somehow sounds familiar.

https://www.news-medical.net/news/20210201/Colchicine-may-have-therapeutic-potential-against-COVID-19.aspx

“ The ideal anti-inflammatory in this setting would be one that is readily available, cheap and orally administered, with a good safety profile, well-tolerated, and that prevents or modulates inflammasome activation. The researchers selected colchicine for their study.”

“ In an earlier experiment, colchicine was found to prevent the activation and recruitment of leukocytes, and thus reduce inflammatory lung injury, and respiratory failure, in acute respiratory distress syndrome (ARDS).”

All you have to do is look chronologically at the announcements to see things are moving forward.

Firstly with the placing in October the announced that they will look at the benefits of using NXP002 alongside existing IPF treatments, which makes sense as the first pre-clinical was to understand whether it worked first and foremost.

"The Board believes the value of NXP002 can be enhanced by studying the benefit of NXP002 in combination with therapies currently marketed for IPF and has prioritised this pre-clinical work, since likely adoption of new therapies for IPF will be on top of current standard of care."

Then in the interims at the end of December, of which Brindley was well on board with, they highlight that this work is underway and to expect results this quarter (Q1 2021). Which imho, will be the precursor to signing any deal.

"Pre-clinical development activities were prioritised to evaluate the benefits of NXP002 alone and in combination with standard of care for the treatment of IPF. Results of this study are expected in the first quarter of 2021."

"Continued discussions with potential partners on licensing lead asset, NXP002, for the Asian market"

Doesn't sound like starting from scratch to me.

Just needs people to buy now, all the talk has been done.

Wonder what the other companies they are in discussions with are saying about what NFX have now.

Thanks Older, I've no qualms about Anne's experience which is great. I'd just like to see a bit more personal belief from her, rather than reading off a script. Blackwell was the same, literally reading his own RNS verbatim.

Older, I get what you're saying, but fundamentally Dans background is not academic, his career has been in business development and driving deals. It was just a ruse by DT's followers to say that he was too much of a scientist.

Older, understandable comments, but the fact she didn't even mention a single product was quite strange. You would expect an incoming CEO to talk about how excited they are to develop such potential and how they are really looking forward to getting results of the pre-clinical.

The irony is that when Dan left, some were saying it was a good thing he was too much of a scientist to run the company.

FX, at the time Blackwell was doing his Phd and Brindley an undergrad.

Wonder if those who were pining for an interview are satisfied now.

Obw, she's been part of Senari Pharma's management team for that time and still is.

FX the story is rather more nuanced than first meets the eye. E.g Blackrock made over $2bn from the GameStop rally, it’s not entirely about the little guys.

Ok, whatever.

Since you are incapable, I've just done the exercise I said you should do. Only Blackwell and Keegan worked together at Vectura before. This was known at the time of his appointment last year.

None of the new board have ever worked at the same company at any point in the past, nor have they worked with any of the older board members.

So, you're case falls apart.

HiHopes, here is a simple task for you.

Go onto LinkedIn, you will find each of the Nufomix board members on there along with the companies they have previously worked for.
Write each of them down and then look for the words that match.

There you'll find your answer. (he says in his best Gandalf voice)

HIHopes.

“ am I correct in thinking this was the name of the Company that a few of the new Board members inc. the C.E.O. that recently joined NFX previously worked for. ”

Simple answer... No you are not correct.

Dissapointing sp today, but its a waiting game at the moment. Nothing new out there that we don't know about.

Its all about Q1 2021.

NXP001 - Oxilio 6 month option expires end of Q1
NXP002 - Innovate funding decision Q1
NXP002 - Pre-clinical study for IPF expected Q1
NXP004 - Pre-clinical study for anti-fibrotic and anti-inflammatory expected Q1
NXP004 - IP being evaluated for improvement of multi-billion dollar drug due Q1
Ebers - RTO further info to be released

Think it depends on who fills out the form.